"Better access to info crucial" for boost in new medtech use
This article was originally published in Clinica
Executive Summary
Patient access to information on new treatment options and the condition itself is crucial to improving healthcare outcomes and even reducing healthcare costs. This is the conclusion of a survey on the value of patient information on the management of chronic disease. The survey, conducted by Pfizer, involved 4,500 patients in eight European countries (Finland, France, Germany, Italy, Poland, Spain, Sweden and the UK) and the US, focusing on the knowledge surrounding asthma, cardiovascular disease and type-2 diabetes.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.